Review: Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review

Abstract

Symptomatic venous thromboembolism (VTE) occurs in 15% of patients with advanced malignancy. Primary thromboprophylaxis using low-molecular-weight heparin (LMWH) is supported by Level 1A evidence but is under-utilized in the palliative setting. A systematic search was performed of Medline, Cochrane Library, EMBASE, AMED, and Web of Science for papers published between 1960 and January 2010 using search terms: ‘palliative’, ‘thromboprophylaxis’, ‘thromboembolism’, ‘heparin’, and ‘advanced cancer’. Forty-two citations were obtained, of which 34 were excluded as they dealt with treatment of VTE, novel anticoagulants, or LMWH as a cancer treatment. Eight original articles were reviewed independently by two authors. Data was extracted according to a predetermined questionnaire. Studies examined practice in specialist palliative care (SPC) units, and attitudes held by a total of 32 physicians and 198 patients. Patients find LMWH acceptable, particularly patients who experienced a sudden decline in performance status. Reluctance to prescribe LMWH is based on physicians’ concerns regarding negative impact on quality of life, and lack of evidence specific to the palliative care setting. In conclusion, LMWH prophylaxis should be implemented in patients with a previously good performance status who have a transiently increased risk of VTE and no contraindications. Further research is required using outcome measures specific to palliative care.

Keywords

Advanced cancer palliative primary thromboprophylaxis thromboembolism

Get full access to this article

View all access options for this article.

References

Johnson MJ , Walker ID , Sproule MW , et al. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haem 1999; 21: 51-54.

Cunningham MS , White B. , O’Donnell J. Prevention and management of VTE in people with cancer: A review of the evidence. Clin Onc 2006; 18: 145-151.

Ambrus JL , Ambrus CM , Mink IB , et al. Causes of death in cancer patients. J Med 1975; 6: 61-64.

Davis MP Hematology in palliative medicine. Am J Hosp Palliat Care 2004; 21: 445.

Lyman GH American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25(34): 5490-5505.

Khorana AA , Connolly GC Assessing risk of venous thromboembolism in the patient with cancer . J Clin Oncol 2009; 27: 4839-4847.

Johnson MJ

How do palliative physicians manage venous thromboembolism?

Pall Med 1997; 11: 462.

Johnson MJ , Sproule MW , Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Onc 1999; 11: 105-110.

Hull RD , Taskob GE , Pineo GF , et al. The low probability lung scan. A need for change in nomenclature . Arch Intern Med 1995; 155: 1845-1851.

10.

Havig O. Deep vein thrombosis and pulmonary embolism-an autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand Suppl 1977; 478: 1-120.

11.

Hospice Directory 2004. Directory of hospice services in the United Kingdom and the Republic of Ireland . London: Hospice Information , 2004.

12.

Noble S. , Nelson A. , Turner C. , et al. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 2006; 332: 577-580.

13.

Kakkar AK , Levine MN , Kadziola Z. , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS) . J Clin Oncol 2004; 22: 10.

14.

Monreal M. , Falga C. , Valdes M. , et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with VTE: findings from the RIETE registry. J Thromb Haemost 2006; 4: 1950-1956.

15.

Khoo CW , Tay K. -H, Shantsila G. , et al. Novel oral anticoagulants. Int J Clin Pract 2009; 63: 630-641.

16.

Levine MN , Deitchman D. , Julian J. , et al. A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol 2009; 27: 15S.

17.

Levine MN New antithrombotic drugs: potential for use in oncology. J Clin Oncol 2009; 27: 4912-4918.

18.

Hirsh J. Executive summary: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 71S-105S.

19.

Monreal M. , Zacharski L. , Jimienez JA , et al. Fixed dose low molecular weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2: 1311-1315.

20.

Weber C. , Merminod T. , Herrmann F. , Zulian G. Prophylactic anti-coagulation in cancer palliative care: a prospective randomized study. Support Care Cancer 2008 ; 16: 847-852.

21.

Kirkova J. , Fainsinger R. Thrombosis and anticoagulation in palliative care: an evolving clinical challenge . J Pall Care 2004; 20: 101-104.

22.

Soto Cardenas MJ , Pelayo-Garcia G. , Rodriduez-Camancho A. , et al. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Pall Med 2008; 22: 965-968.

23.

Noble S. , Finlay G. Have palliative care teams’ attitudes towards venous thromboembolism changed? A survey of thromboprophylaxis practice across British specialist palliative care units in the years 2000 and 2005. J Pain Symp Mgt 2006; 32: 38-43.

24.

Brabin ET , Douglas E. , Mackay C. , et al. The role of primary thromboprophylaxis in hospice patients: a retrospective review of current practice. Pall Med 2008; 22: 569-603.

25.

Kierner K. , Gartner V. , Schwarz M. , et al. Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation . Am J Hosp Palliat Care 2008; 25: 127-131.

26.

Noble S. , Nelson A. , Finlay IG Factors influencing hospice thromboprophylaxis policy: a qualitative study . Pall Med 2008; 22: 808-813.

27.

Pace V. , Hall E. , Bailey C. Prophylactic heparin in palliative care-a cautious welcome. BMJ 2006; 332: 728-729.

28.

Chambers JC Prophylactic heparin in palliative care: to a challenging idea. BMJ 2006; 332: 729.

29.

Noble S. Is low molecular weight heparin an acceptable intervention in palliative care patients? A phenomenological study. Pall Med 2004; 18: 150.

30.

Noble SIR , Finlay IG Is long-term low-molecular weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study . Pall Med 2005; 19: 197-201.